Also found in: Medical.
Ad5Adenovirus Type 5
Ad5Alzheimer Disease 5 (gene)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The company said the RT-100 AC6 gene transfer involves infusing an inactivated adenovirus vector encoding human adenylyl cyclase type 6 (Ad5.hAC6) into the arteries that feed the heart during cardiac catheterization, a commonly performed procedure.
A dual-regulated adenovirus variant CNHK500, in which human telomerase reverse transcriptase (hTERT) drove the Ad5 E1a gene and hypoxia-response promoter controlled the E1b gene, was engineered.
It remained in use until the last edition of the KS, but it is particularly frequent in Ad5, though it still remains a minor variant, even in this edition.
The STEP HIV vaccine trial was designed to evaluate the safety and efficacy of the Merck Ad5 vaccine.
Mouse 4-8 cell embryos can be infected with [greater than or equal to] [10.sup.6] pfu/ml Ad5 vectors with about 50% efficiency (Figure 1).
The recent failures of the Merck Ad5 STEP and Phambili trials resulted in questions being asked on relevance of the current vaccine approaches in both the scientific community and the general public (25).
Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
Three of these are ongoing, namely HVTN 204, a phase II trial assessing the safety and immunogenicity of a multiclade HIV-1 DNA vaccine boosted by a multiclade HIV-1 Ad5 vaccine in HIV-uninfected adults, in which 240 of the 480 participants are South Africans who have received all their vaccinations and are being followed up for long-term safety and immunogenicity; the SAAVI 102/HVTN 073 trial, investigating the multigene sub-type C SAAVI DNAC2 and MVA-C vaccine, a phase I trial currently enrolling participants, of whom 36 out of the 48 will be enrolled in South Africa; and the HVTN 503 phase IIB trial, in which 801 participants are being followed up after further enrolments and vaccinations were halted.
(19,20) An interim analysis found that, among people with a prestudy adenovirus 5 (Ad5) antibody titer below 201, 24 of 741 people (3%) getting the vaccine and 21 of 762 (3%) getting dummy shots picked up HIV infection.
Meanwhile, they inclined by 24.5% y-o-y, as they represented AD5,228.9bn in 2006.
Although the difference in infection rates between the vaccine and placebo groups across the entire study population was only "marginally statistically significant," in the subgroup of participants with high levels of adenovirus type 5 (Ad5) immunity--defined as antibody levels greater than 200 U--the statistical significance between the two groups was more robust.